Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences
PRESS RELEASE Development of MammaPrint®, first FDA-cleared molecular diagnostic test Read More
Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
Agendia COVID-19 Statement
As a valued customer we wanted to reach out and Read More
Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer
PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Read More
Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020
PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Read More
Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse
PRESS RELEASE Breast Cancer Patients in Germany Now have Insurance Read More
PROMIS study findings presented at SABCS 2019
PRESS RELEASE New Data Compare Genomic Profiling Results for Premenopausal Read More
Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients
PRESS RELEASE Data evaluating MammaPrint® and BluePrint® includes new risk Read More
Agendia Presents New Data on the Biological Characteristics of Patients within Extreme Low Risk and High Risk MammaPrint Subgroups at the European Society for Medical Oncology (ESMO)
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
